


Hot Topics in Atherosclerosis and Cardiovascular Disease



DATES:	Wednesday 4 – Friday 6 July 2018	Accreditation / endorsement: CPD via the Royal College of Physicians – applied for British Dietetic Association endorsement (BDA) – endorsed ✓
LOCATION:	Warwick Arts Centre, University of Warwick, Coventry CV4 7AL	
CONFERENCE ORGANISING COMMITTEE:		
CHAIR:	<i>Dr Nigel CAPPS</i> - Consultant Chemical Pathologist, Telford	
LOCAL HOSTS:	<i>Professor Elizabeth HUGHES</i> - Director of Education and Quality HEE (London and South East); West Midlands Regional Postgraduate Dean, Birmingham <i>Professor Mike KHAN</i> - Associate Professor of Medicine at the University of Warwick, Coventry	
COMMITTEE:	<i>Mr Stephen BOLEY</i> – Chairman, HEART UK <i>Dr Dev DATTA</i> - Consultant in Biochemistry & Metabolic Medicine, Cardiff, Wales <i>Dr Arun GUPTA</i> – GP, South Lewisham <i>Linda MAIN</i> – Dietetic Advisor, HEART UK <i>Mrs Michaela NUTTALL</i> - vice chair Healthcare Committee <i>Jules PAYNE</i> – Chief Executive, HEART UK <i>Dr Alan REES</i> – Medical Director, HEART UK <i>Dr Handrean SORAN</i> – Consultant Physician & Endocrinologist / Honorary Senior Lecturer, Manchester	

PROGRAMME SUMMARY:

	MORNING	MID MORNING	MIDDAY	AFTERNOON	EVENING
WED	Hyperlipidaemia Education + Lp(a) Study Day HEART UK Committee Meetings				Sponsored Symposia 1 2 3 HEART UK Annual General Meeting Welcome Buffet Reception
THURS	Medical + Scientific Programme Primary + Health Care Programme			Clinical Lipidology Live! Heart Healthy Walk Myant Lecture	Conference Dinner and dance
FRI	Moderated Poster Session Medical + Scientific Programme Abstract Session Primary + Health Care Programme Abstract Session			Presentation of Abstract Prizes Closing Debate	

WEDNESDAY 4 JULY

07:00 – 09:00	BREAKFAST (residential guests only)	1 st floor, Rootes Building Restaurant
08:00	REGISTRATION OPENS	Arts Centre foyer
09:00 – 10:30 (1hr 30 mins)	HEART.UK MS&R Committee meeting Chair: Handrean Soran Deputy Chair: Dev Datta	National Grid Room, 1 st floor, Arts Centre
09:00 – 11:00	STUDY DAY REFRESHMENTS	Butterworth Hall, Arts Centre
11:00 – 17:00	Exhibition build	Mead Gallery, 1 st floor, Arts Centre
11:00 – 16:15	Hyperlipidaemia Education + Lp(a) Study Day: <i>Invitation to: Primary care • GP's • GP Registrars • Cardiovascular and Lipid Clinic Nurses • Practice Nurses • Genetics Specialist Nurses • Dietitians • Nutritionists • Scientists • PhD students • Consultants • SpR's working within clinical chemistry, endocrine and diabetes • Nurses and others involved in the field of lipidology and cardiovascular risk.</i> Organised by: Handrean SORAN	Cinema, Arts Centre
	Co-Chairs: Handrean SORAN + Safwaan ADAM	
11:00 – 11:30 (30 mins)	SPEAKER 1: Optimising treatment of Hyperlipidaemia: quantitative evaluation of UK, USA and European guidelines Evidence strongly favours therapeutic LDL concentration targets in hypercholesterolaemia Professor Paul DURRINGTON Professor of Medicine Division of Cardiovascular Sciences, University of Manchester Manchester, UK	
11:30 – 11:40	Discussion	
11:40 – 12:05 (25 mins)	SPEAKER 2: Cardiovascular risk in chronic kidney disease and its management Professor Phil KALRA Consultant Nephrologist, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, UK	
12:05 – 12:15	Discussion	
12:15 – 12:40 (25 mins)	SPEAKER 3: Lipodystrophy Dr Anna STEARS Consultant in Diabetes and Endocrinology National Severe Insulin Resistance Service, Wolfson Diabetes & Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK	
12:40 – 12:50	Discussion	
12:50	Session close	
12:50 – 13:50	STUDY DAY LUNCH + NETWORKING	Butterworth Hall, Arts Centre
13:30 – 16:00 (2hr 30 mins)	HEART UK Board meeting HOST: Jules Payne	National Grid Room, 1 st floor, Arts Centre
13:50 – 16:15	Hyperlipidaemia Education + Lp(a) Study Day continued: Supported by:  A subsidiary of Ionis Pharmaceuticals, Inc.	Cinema, Arts Centre

	Co-Chairs: <i>Jai CEGLA + Benjamin JONES</i>	
13:50 – 14:15 (25 mins)	SPEAKER 5: Lipoprotein(a): its value as a CV risk factor and how to address it <i>Professor Klaus G. PARHOFER</i> Medizinische Klinik IV – Grosshadern, Klinikum der Universität München, München, GERMANY	
14:15 – 14:25	Discussion	
14:25 – 14:50 (25 mins)	SPEAKER 6: Lp(a) in children <i>Professor Kurt WIDHALM</i> Professor for Clinical Nutrition and Pediatrics President: Academic Institute for Clinical Nutrition Vienna, AUSTRIA	
14:50 – 15:00	Discussion	
15:00 – 15:15	Comfort break	
	Co-Chairs: <i>Michael FRANCE (TBC) + Ahai LUVAI</i>	
15:15 – 15:40 (25 mins)	SPEAKER 7: Lipoprotein (a) as a therapeutic target <i>Dr Tina KHAN</i> Cardiology ST7 RBHT/Academic Clinical Lecturer Imperial College, London, UK	
15:40 – 15:50	Discussion	
15:50 – 16:10 (20 mins)	SPEAKER 8: Lp(a) – my story <i>Mrs Sandra REVILL TREMULIS</i> President and Founder Lipoprotein(a) Foundation, San Carlos, CA, USA	
16:10 – 16:15	Discussion	
16:15	Close of session	
16:30 – 18:00 (1hr 30 mins)	HEART UK Health Care Committee meeting HOST: <i>Linda Main</i>	<i>National Grid Room, 1st floor, Arts Centre</i>
16:30 - 17:10 (40 mins)	SPONSORED SYMPOSIA 1:  <i>Programme development by sponsor</i>	<i>Butterworth Hall, Arts Centre</i>
17:10 – 17:20	Changeover	
17:20 – 18:00 (40 mins)	SPONSORED SYMPOSIA 2:  <i>A subsidiary of Ionis Pharmaceuticals, Inc.</i> <i>Programme development by sponsor</i>	<i>Butterworth Hall, Arts Centre</i>
18:00 – 18:10	Changeover	
18:10 – 18:50 (40 mins)	SPONSORED SYMPOSIA 3:	<i>Butterworth Hall, Arts Centre</i>

Programme development by sponsor

18:50	Welcome drinks available		
19:00 – 19:30	HEART UK AGM		Butterworth Hall OR National Grid Room Arts Centre
19:30 – 22:00	WELCOME BUFFET RECEPTION		Mead Gallery, 1 st floor, Arts Centre
19:40 – 19:45	HEART UK welcome <i>Mr Stephen BOLEY</i> , Chairman, HEART UK		
19:45 – 19:50	SPONSOR WELCOME		
19:50	CATERING: Fork buffet served		
22:00	Evening concludes		

THURSDAY 5 JULY

07:00 – 09:00	BREAKFAST (residential guests only)		1 st floor, Rootes Building Restaurant
08:00	REGISTRATION OPENS		Arts Centre foyer
08:00 – 09:00	Lipid Interest Group meeting HOST: <i>Alison POTTLE</i>		Chancellors, 2 nd floor, Rootes Building
08:30 – 09:10	REFRESHMENTS, NETWORKING + EXHIBITION		Mead Gallery, 1 st floor, Arts Centre
09:10 – 11:00	SESSION A: Medical & Scientific Hot Topics in Atherosclerosis – Part One		Butterworth Hall, Arts Centre
09:10 – 09:20 (10 mins)	Introduction: <i>Mr Stephen BOLEY</i> , Chairman, HEART UK <i>Dr Alan REES</i> , Medical Director, HEART UK		
Co-chairs: <i>Nigel CAPPS</i> + <i>Mike KHAN</i> (tbc)			
09:20 – 09:40 (20 mins)	PLENARY SPEAKER 1: CETP inhibition – the Oxford REVEAL study This talk will describe the story of CETP inhibition to date, and the results of the 30,000-patient REVEAL trial of anacetrapib. <i>Dr Louise BOWMAN</i> Associate Professor of Clinical Trials and Epidemiology University of Oxford, Nuffield Department of Population Health, Oxford, UK		
09:40 – 09:45	Discussion		
09:45 – 10:05 (20 mins)	PLENARY SPEAKER 2: HDL – reasons of previous clinical futility and opportunities for future clinical utility <i>Professor Arnold VON ECKARDSTEIN</i> Professor of Clinical Chemistry, University of Zurich Director, Institute of Clinical Chemistry of the University Hospital of Zurich, SWITZERLAND		
10:05 – 10:10	Discussion		
10:10 – 10:30	PLENARY SPEAKER 3:		

	(20 mins)	Inflammation / Coronary Artery Disease (CAD) / CANTOS <i>Professor Sheila FRANCIS</i> Professor of Cardiovascular Biology – Head of Department Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield Sheffield, UK		
	10:30 – 10:35	Discussion		
	10:35 – 10:55	PLENARY SPEAKER 4: Inclisiran – the story so far Exploring the mechanism of action of inclisiran, data from early phase trials, details of ongoing studies and plans for a forthcoming cardiovascular outcome trial. <i>Dr David PREISS</i> Associate Professor University of Oxford, Nuffield Department of Population Health, Oxford, UK		
	(20 mins)			
	10:55 – 11:00	Discussion		
11:00 – 11:30	REFRESHMENTS, NETWORKING + EXHIBITION		<i>Mead Gallery, 1st floor, Arts Centre</i>	
11:30 – 13:15	SESSION B: Medical & Scientific Hot Topics in Atherosclerosis – Part Two <i>Butterworth Hall, Arts Centre</i>		SESSION C: Primary & Health Care <i>Cinema, Arts Centre</i>	
	Co-chairs: <i>Dec DATTA</i> + <i>Gordon FERNS</i> (tbc)		Co-chairs: <i>Alan BEGG</i> + <i>Michaela NUTTALL</i>	
	11:30 – 12:00 (30 mins)	SPEAKER 5: Non alcoholic fatty liver disease (NAFLD) update NAFLD is very common in patients with CVD risk factors: how should NAFLD be diagnosed and which patients should be referred for specialist investigation? <i>Professor Christopher D BYRNE</i> Professor Endocrinology & Metabolism Human Development and Health Academic Unit Faculty of Medicine University of Southampton, Southampton General Hospital Southampton, UK	11:30 – 12:00 (30 mins)	HC SPEAKER 5: Public health and primary care commissioning for vascular health <i>Mrs Gillian FIUMICELLI</i> Head of Vascular Disease Prevention Programme Public Health Bromley, London Borough of Bromley, UK
	12:00 – 12:05	Discussion	12:00 – 12:05	Discussion
	12:05 – 12:35 (30 mins)	SPEAKER 6: Bariatric Surgical Approaches in managing Obesity <i>Mr John BARRY</i> Surgeon Welsh Institute of Metabolic and Obesity Surgery, Morriston Hospital, Swansea, Wales, UK	12:05 – 12:35 (30 mins)	HC SPEAKER 6: Cardiovascular disease: lifetime risk for women <i>Dr Jane FLINT BRIDGEWATER</i> Hon Consultant Cardiologist Chair BCS Joint Working Group Recommendations for Women’s Heart Health 2007
	12:35 – 12:40	Discussion	12:35 – 12:40	Discussion
	12:40 – 13:10 (30 mins)	SPEAKER 7: Metabolic improvements in patients with impaired glucose homeostasis following Bariatric Surgery <i>Professor Jeffrey STEPHENS</i> Clinical Professor of Diabetes, Swansea University Consultant Physician, Morriston Hospital Swansea, Wales, UK	12:40 – 13:10 (30 mins)	HC SPEAKER 7: Men and CVD <i>Professor Mike KIRBY</i> Visiting Professor, University of Hertfordshire and The Prostate Centre, London, UK
	13:10 – 13:15	Discussion	13:10 – 13:15	Discussion
13:15 – 14:30 (75 mins)	LUNCH, NETWORKING + EXHIBITION		<i>Mead Gallery, 1st floor, Arts Centre</i>	
13:15 – 14:30	Simon Broome Committee meeting		<i>National Grid Room, 1st floor, Arts Centre</i>	

	Host: <i>Nigel CAPPS</i>	
14:30 – 16:00	Clinical Lipidology Live! Interactive case study session in a panel format with perspectives from a cardiologist, lipidologist and GP Organiser: Dev Datta Facilitator: <i>Dr Dev DATTA</i> Consultant in Biochemistry & Metabolic Medicine, Cardiff, Wales	Butterworth Hall, Arts Centre
16:00 – 16:30 (45 mins)	Heart healthy walk Host: HEART UK Fundraising Manager, <i>Charlotte HOARE</i> will be leading this heart healthy walk designed to energise everyone at the end of a busy day! Depart from Woods-Scawen Room after Clinical Lipidology Live	
16:00 – 16:45	REFRESHMENTS, NETWORKING + EXHIBITION	Mead Gallery, 1 st floor, Arts Centre
16:45 – 18:00	SESSION D: Medical & Scientific Chair: <i>Alan REES</i> 16:45 – 17:00 (15 mins) HEART UK CHARITY UPDATE <i>Miss Jules PAYNE</i> Chief Executive, HEART UK 17:00 – 18:00 (60 mins) SPEAKER 9: MYANT LECTURE: <i>Professor Bart STAELS</i> Lille, FRANCE NO Q+A	Butterworth Hall, Arts Centre
18:00	Conference close	
19:15 – 19:45	CONFERENCE PRE DINNER DRINKS	Helen Martin Studio, Arts Centre
19:45 - 23:30	CONFERENCE DINNER AND ENTERTAINMENT	Butterworth Hall, Arts Centre
23:30	Bar closes	
24:00	Evening concludes	

FRIDAY 6 JULY		
07:00 – 09:00	BREAKFAST (<i>residential guests only</i>)	1 st floor, Rootes Building Restaurant
08:00	REGISTRATION OPENS	Arts Centre foyer
08:00 – 09:00	Apheresis Working Group meeting Host: <i>Dev DATTA</i>	National Grid Room, 1 st floor, Arts Centre
08:30 – 09:30	REFRESHMENTS, NETWORKING + EXHIBITION	Mead Gallery, 1 st floor, Arts Centre
08:35 – 09:35	Moderated + Unmoderated Poster Session Judging panel: <i>Chris BYRNE</i> (TBC), <i>Mike KHAN</i> (TBC), <i>Alan REES</i> , <i>Bart STAELS</i> (TBC) Moderated Posters 1 USABILITY OF A WEBTOOL TO ASSIST DECISIONS ON GENOTYPING FOR FAMILIAL HYPERCHOLESTEROLAEMIA – RESULTS FROM A CLINICAL PILOT <i>Ashfield-Watt PAL*</i> , <i>Haralambos K</i> , <i>Sharif B</i> , <i>McDowell IFW</i> . FH Wales Research Team, Cardiff University, Wales Heart Research Institute, Heath Park, Cardiff, CF14 4XN 2 AUDIT OF PCSK9 INHIBITOR PRESCRIBING IN THE NORTH EAST OF ENGLAND	Mead Gallery, 1 st floor, Arts Centre

Banerjee P^{1}, Neely RDG¹, Pattman S², Artham.S³, Carey P³*

¹Department of Blood Sciences, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK

²Department of Blood Sciences, Northumbria Healthcare NHS Foundation Trust, UK

³Department of Endocrinology, City Hospitals Sunderland Foundation Trust

3

SUSTAIN 6: A POST-HOC ANALYSIS OF THE EFFECT OF SEMAGLUTIDE ON CARDIOVASCULAR OUTCOMES OVER TIME IN SUBJECTS WITH TYPE 2 DIABETES

Bellary S^{1}, Jodar E², Seufert J³, Damgaard LH⁴, Gaarsdal Holst A⁴, Leiter L.⁵*

¹Aston University, Birmingham, UK; ²Universidad Europea de Madrid, Madrid, SPAIN; ³University of Freiburg, Freiburg, Germany; ⁴Novo Nordisk, Soborg, DENMARK; ⁵Li Ka Shing Knowledge Institute and University of Toronto, ON, CANADA

4

HYPERCHOLESTEROLEMIA WITH LOW VERSUS HIGH LIKELIHOOD OF POLYGENIC ORIGIN: A SINGLE CENTRE EXPERIENCE

*A. David^{*1}, J. Cegla¹, S. Walji¹, B. Jones¹, S. Haboosh¹, F. De Lorenzo¹, J. Scott¹, G.R. Thompson¹*

¹Lipid Clinic, Hammersmith Hospital, Imperial NHS Trust, London, UK

5

PATIENT EXPERIENCE AT A DEDICATED MULTIDISCIPLINARY NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) CLINIC ENCOMPASSING CARDIOVASCULAR RISK ASSESSMENT AND MANAGEMENT. A NEW MODEL OF CARE?

Goyale A^{1}, Misas MG², Roccarina D², Nair DR¹ and Tsochatzis E²*

Royal Free London NHS Foundation Trust, London, NW3 2QG

UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London

6

THE IMPACT OF SOCIO-ECONOMIC STATUS ON CASE FINDING FOR FAMILIAL HYPERCHOLESTEROLAEMIA

L. Gritzmacher^{1}, K. Haralambos², P. Downie¹, G. Bayly¹.*

¹ Department of Biochemistry, University Hospitals Bristol NHS Foundation Trust, Bristol, UK

² BHF FH Register (PASS) Coordinator, Cardiff University, Cardiff, UK

7

UNUSUAL PRESENTATION OF RHABDOMYOLYSIS AFTER CO-ADMINISTRATION OF STATIN AND CLARITHROMYCIN

O. Kirresh^{}, C. Lunken*

Department of Endocrinology, University College London Hospitals, UK.

8

DUAL PATHOLOGY FOR PANCREATITIS IN PREGNANCY

O. Kirresh^{}, U. Srirangalingam, C. Lunken*

Department of Endocrinology, University College London Hospitals, UK.

9

SETTING UP A REGIONAL FH SERVICE; A SUMMARY OF THE ACHIEVEMENTS AND CHALLENGES

*K Mitchell^{*1}, J Webster¹, C Tuson², C Burton¹, P Sutton³, R Dunn³, D Chandrayay², D Narayanan³, M Mansfield⁴, J Barth⁴, A Bandyopadhyay², K Haralambos⁵ B Power⁶ J Jessop⁶*

¹Calderdale and Huddersfield NHS Trust, England; ²York Teaching Hospitals NHS Foundation Trust, England; ³Hull Teaching Hospitals NHS Trust, England; ⁴Leeds Teaching Hospitals NHS Trust, England; ⁵Cardiff and Vale University Hospitals Board, Wales; ⁶Yorkshire and Humber Strategic Clinical Network

10

AN EXPERIENCE OF DEDICATED FH SERVICE IMPLEMENTATION IN HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST

Paula Sutton¹, Rachel Dunn¹, Rob Desborough¹, Mohammed Malik², Aditi Bandyopadhyay³, Kate Haramblos⁴, Deepa Narayanan¹.

¹Hull and East Yorkshire Hospitals NHS Trust

²North Lincolnshire and Goole Hospitals NHS Trust

³York Teaching Hospitals NHS Trust

⁴PASS coordinator, Wales.

11

EFFECT OF COMBINATION THERAPY WITH PCSK9 INHIBITORS AND LIPOPROTEIN APHERESIS

*A Pottle**, *C Browne*, *E Neves*, *M Barbir*
Cardiology Department, Harefield Hospital, Royal Brompton & Harefield NHS Foundation Trust, London. UK

12

THE EFFECT OF EXERCISE TRAINING ON LIPID PROFILE: A SYSTEMATIC REVIEW AND META-ANALYSIS

Gina Wood, *Neil A. Smart*

University of New England, Armidale, NSW Australia 2350.

Unmoderated Posters

13

A QUALITY IMPROVEMENT PROJECT: OPTIMISING LIPID LOWERING DIETARY ADVICE VIA GROUP EDUCATION SESSIONS FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE

D. Barrese^{1*}, *A. Lang*¹, *M. Crook*^{2*}, *A. Nassor*^{1*}, *D. Gray*¹, *M. Kagka*^{1*}

¹Department of Nutrition and Dietetics, Guy's and St Thomas' NHS Foundation Trust, London, UK

²Consultant in Clinical Biochemistry and Metabolic Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK

14

A CASE OF RESISTANCE TO PCSK9 INHIBITOR TREATMENT

*R. Chaudhry*¹, *A. Viljoen*¹

¹Department of Chemical Pathology, Lister Hospital, Stevenage, SG1 4AB, UK

15

METABOLIC SYNDROME CRITERIA AND SUBCLINICAL VASCULAR DISEASE IN ELDERLY MEN

EA Ellins^{1*}, *LT Lennon*², *O Papacosta*², *SG Wannamethee*², *PH Whincup*³, *JP Halcox*¹

¹Institute of Life Sciences, Swansea University Medical School,

²UCL Department of Primary Care & Population Health, UCL Medical School,

³Division of Population Health Sciences and Education, Population Health Research Institute, St George's University of London

16

LCAT DEFICIENCY- A CASE REPORT

*Jain A**, *Hoshi N*, *Defesche J*¹, *Nair D R*

Department of Clinical Biochemistry, Royal Free London NHS Foundation Trust, London, NW3 2QG.

¹Molecular Diagnostic Laboratory, Department of Vascular Medicine, Academic Medical centre, Amsterdam, NL-1105 AZ, The Netherlands.

17

PCSK9 INHIBITORS- FITTING THEM INTO ROUTINE PRACTICE IN A LIPID CLINIC

*Jain A**, *Harvey D*, *Hoshi N*, *Sharifi M*, *Dhalla S*¹, *Nair DR*

Department of Clinical Biochemistry, Royal Free London NHS Foundation Trust, London, NW3 2QG. ¹Pharmacy, Royal Free London NHS Foundation Trust, London, NW3 2QG.

18

EXAMINING THE BURDEN OF ILLNESS IN PATIENTS WITH FAMILIAL CHYLOMICRONAEMIA SYNDROME: RESULTS OF THE IN-FOCUS STUDY, UNITED KINGDOM RESPONDENTS

*Handrean Soran*¹, *Michael Stevenson*², *Karren Williams*², *Brant Hubbard*², *Richard Jones*^{*2}, *Basil Issa*³

¹Manchester University Hospital NHS Trust, Manchester, UK; ²Akcea Therapeutics Inc., Cambridge, MA, USA; ³Department of Endocrinology, University Hospital of South Manchester, Wythenshawe, UK

19

SITOSTEROLAEMIA AS A CAUSE OF TENDON XANTHOMATA IN A PATIENT WITH HYPERLIPIDAEMIA

Ian McDowell^{*1,3}, *Emily Capener*², *Heather Wheatley*³, *Peter Clayton*⁴, *Andrew Goringe*⁵

¹Cardiff University School of Medicine; ²Dept of Dietetics, Cardiff and Vale University Health Board; ³Dept of Medical Biochemistry and Immunology, Cardiff and Vale University Health Board

⁴UCL Great Ormond Street Institute of Child Health; ⁵Dept of Haematology, Cardiff and Vale University Health Board

20

MEASUREMENT OF ABSORPTION STEROLS IN PATIENTS WITH HYPERCHOLESTEROLAEMIA: IMPROVED DIAGNOSTIC PERFORMANCE WHEN STEROL/CHOLESTEROL RATIOS ARE REPORTED

A Bowron, E Middling, M Appleton, C Boot, D Neely*
Department of Blood Sciences, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK.

21
LIPID MANAGEMENT WITH PCSK9 INHIBITORS - COMBINATION OR MONOTHERAPY? EXPERIENCE FROM A TERTIARY CARDIAC CENTRE

Neves E*, Browne C, Breen J, Davis L, Hayes C, Manning S, Priestley-Barnham L, Barbir M.
Royal Brompton & Harefield NHS Foundation Trust

22
REVIEW AND ANALYSIS OF A SINGLE CENTRES FIRST ONE HUNDRED PATIENTS PRESCRIBED PCSK9 THERAPY

K Peers*¹ S Ramachandran ^{2,3} A Jones ⁴
1 Advanced Nurse Practitioner in Department of Clinical Chemistry, Heartlands Hospital, Birmingham, England 2 Professor Metabolic Medicine, Department of Clinical Chemistry, Good Hope Hospital, Birmingham, England 3 Research in Metabolic medicine, Warwick University, Midlands, England 4 Consultant Physician in Clinical Chemistry, Heartlands Hospital, Birmingham, England

23
COMPARISON OF THE SURVIVAL BETWEEN CABG VS. PCI PROCEDURES IN PATIENTS WITH POOR LEFT VENTRICULAR FUNCTION (EJECTION FRACTION <30%): A PROPENSITY-MATCHED ANALYSIS.

Shaneel Shah
University of Bristol; Department of Cardiac Surgery, Bristol Heart Institute, Bristol, UK

24
RECRUITING FAMILIAL HYPERCHOLESTEROLAEMIA (FH) PATIENTS TO THE 100,000 GENOME PROJECT. THE EXPERIENCE OF SPECIALIST NURSES IN THE WESSEX FH SERVICE

Sherman, CI*, Cazeaux, A
Wessex Familial Hypercholesterolaemia Genetics Service, Clinical Genetics, G Level, Princess Anne Hospital, Coxford Road, Southampton. SO16 5YA

SESSION E: Medical & Scientific

Butterworth Hall, Arts Centre

Focus on Diabetes

09.45 – 09:50 **Opening remarks:** Alan REES, Medical Director, HEART UK

Chair: Dermot NEELY (TBC)

09:50 – 10:20
(30 mins) **PLENARY SPEAKER 10:**
Genomics Update

10:20 – 10:30 Discussion

10:30 - 11:00 **REFRESHMENTS, NETWORKING + EXHIBITION**

Mead Gallery, 1st floor, Arts Centre

SESSION F: Medical & Scientific Abstracts of Free Comms

Butterworth Hall, Arts Centre

SESSION G: Primary & Health Care Abstracts of Free Comms

Cinema, Arts Centre

Co-chairs: Julian HALCOX + JAI CEGLA (TBC)

Co-chairs: Alison POTTLE + Suzanne WATKINS

11:00 – 11:10
1/
HIGH RATES OF NON-ADHERENCE TO ANTIDIABETIC, ANTIHYPERTENSIVE AND LIPID LOWERING TREATMENT IN PATIENTS WITH TYPE 2 DIABETES REVEALED LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY (LC-MS/MS) URINE ANALYSIS
Gupta P^{1,2}, Mohamed AA¹, Patel P¹, Burns A¹, Saeed M¹, Lane D¹, Seidu S^{3,4} and Khunti K^{3,4}
¹Department of Metabolic Medicine and Chemical Pathology, University Hospitals of Leicester NHS Trust, UK
²Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
³Leicester Diabetes Centre, Leicester General Hospital, Leicester, UK
⁴Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK

11:00 – 11:10
6/
COST-EFFECTIVENESS OF UNIVERSAL SCREENING FOR FAMILIAL HYPERCHOLESTEROLAEMIA (FH) AT AGE 1-2 YEARS
A.J. McKay¹, H. Hogan², S.E. Humphries^{3*}, D. Marks⁴, K.K. Ray⁵, A. Miners²
¹London School of Hygiene and Tropical Medicine (LSHTM), London, UK;
²Department of Health Services Research and Policy, LSHTM, UK;
³Cardiovascular Genetics, UCL, UK; ⁴Department of Public Health, Environments and Society, LSHTM, UK; ⁵Department of Primary Care and Public Health, Imperial College London, UK.

11:10 – 11:15 Discussion

11:10 – 11:15 Discussion

11:15 – 11:25	<p>2/ CAN MONOGENIC SEVERE HYPERTRIGLYCERIDEMIA BE DIFFERENTIATED FROM POLYGENIC FORMS THROUGH CLINICAL FEATURES: DATA FROM APPROACH AND COMPASS STUDIES IN FCS AND NON-FCS HYPERTRIGLYCERIDEMIC PATIENTS? <i>Louis O'Dea¹, James MacDougall², Andres Digenio, Brant Hubbard¹, Marcello Arca³, Patrick Moriarty⁴, John Kastelein⁵, Eric Bruckert⁶, Handrean Soran^{*7}</i> ¹AkceaTherapeutic Inc., Cambridge, MA, USA; ²BioBridges, Wellsley, MA, USA; ³Department of Internal Medicine and Allied Sciences, La Sapienza University of Rome, Rome, Italy; ⁴Department of medicine, Division of Clinical pharmacology, University of Kansas Medical Center, Kansas City, Kansas; ⁵Department of Vascular Medicine, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, Netherlands; ⁶Institut E3M et IHU Cardiometabolique (ICAN), Hôpital Pitié-Salpêtrière, Paris, France; ⁷Manchester University Hospital NHS Trust, Manchester, UK</p>	11:15 – 11:25	<p>7/ FAMILIAL HYPERCHOLESTEROLAEMIA IN THE GENOMIC ERA: IMPROVING THE CLINICAL UTILITY OF CURRENT GENETIC TESTING <i>Knowles C1[*], Hills A¹, Watson E¹, Pennock M², Dent C¹, Evans J¹, Robinson C¹, Woodward G¹, Wadsley M¹, Honeychurch J¹, Williams M¹</i> ¹Bristol Genetics Laboratory, Bristol, UK</p>
11:25 – 11:30	Discussion	11:25 – 11:30	Discussion
11:30 – 11:40	<p>3/ PROTEIN STRUCTURE ANALYSIS AIDS IN THE INTERPRETATION OF GENETIC VARIANTS OF UNCERTAIN CLINICAL SIGNIFICANCE IDENTIFIED IN THE LDL RECEPTOR <i>A. David¹, S. Ittisoponpisan¹, M.J.E. Sternberg¹</i> Centre for Structural Biology, Department of Life Sciences, Imperial College London, London, UK</p>	11:30 – 11:40	<p>8/ FAMILIAL HYPERCHOLESTEROLAEMIA (FH) GENETIC TESTING IN THE UK <i>Haralambos K^{1*}, Humphries SE², Whitmore J³, Datta D⁴, Cather M⁵, Miedzybrodzka Z⁶, Breen J⁷, Gritzmacher L⁸, Hamlen A⁹, Potter A¹⁰, Cazeaux A¹¹, Sherman C¹², Moore A¹², Tyler M¹², Burton C¹³, Webster J¹³, Tuson C¹³, Sutton P¹³, Dunn R¹³, Nicholson K¹⁴, Harvey D¹⁵, Jayne Z¹⁵, Maughan D¹⁶, McDowell IFW¹</i> ¹Cardiff University, ²Institute Cardiovascular Sciences, London, ³British Heart Foundation, ⁴All Wales FH Cascade Testing Service, ⁵Northern Ireland FH Service, ⁶Scottish FH Service, ⁷Harefield, London FH Service, ⁸Bristol and Bath FH Service, ⁹Gloucestershire FH Service, ¹⁰North East England FH Service, ¹¹Wessex FH Service, ¹²South Yorkshire & North Derbyshire FH Service, ¹³Yorkshire & Humber FH Service, ¹⁴Manchester FH Service, ¹⁵Royal Free FH Service, ¹⁶Doncaster FH Service, UK</p>
11:40 – 11:45	Discussion	11:40 – 11:45	Discussion
11:45 – 11:55	<p>4/ CORONARY HEART DISEASE MORTALITY IN SEVERE AND NON-SEVERE FAMILIAL HYPERCHOLESTEROLAEMIA: DATA FROM THE UK SIMON BROOME FH REGISTER <i>S.E. Humphries^{1*}, J.A. Cooper¹, M. Seed², N. Capps³, P.N. Durrington⁴, B. Jones⁵, I.F.W. McDowell⁶, H. Soran⁷, H.A.W. Neil⁸ on behalf of the Simon Broome FH Register Group</i> ¹Cardiovascular Genetics, UCL, London, ²Cardiology, Charing Cross Hospital, U of London; ³Clinical Biochemistry, Princess Royal Hospital, Telford; ⁴Cardiovascular Research Group, U of Manchester; ⁵Investigative Medicine, Imperial College London, ⁶Medical Biochemistry and Immunology, U Hospital of Wales, Cardiff; ⁷Central Manchester University Hospitals, Manchester; ⁸Wolfson College, University of Oxford, UK</p>	11:45 – 11:55	<p>9/ WHAT DIETETIC SUPPORT IS AVAILABLE TO PATIENTS IN OUTPATIENT LIPID CLINICS IN THE UK? <i>Kinnear, F.J.*¹, Lithander, F.E.¹, Hamilton-Shield, J.P.¹, Main, L.²</i> ¹NIHR Bristol Biomedical Research Centre (Nutrition theme), Bristol, U.K. ²HEART UK- The Cholesterol Charity, Maidenhead, U.K.</p>
11:55 – 12:00	Discussion	11:55 – 12:00	Discussion
12:00 – 12:10	<p>5/ AUTOSOMAL RECESSIVE HYPERCHOLESTEROLAEMIA DUE TO HOMOZYGOUS LDLRAP1 VARIANTS: A BRISTOL CASE REVIEW <i>Honeychurch J^{1*}, Hills A¹, Watson E¹, Pennock M¹, Dent C, Evans J, Robinson C, Woodward G², Wadsley M³, Morris A², Cramb, R³, Dawson C³, Soran H⁴, Nicholson K⁴, Williams M¹</i> ¹Bristol Genetics Laboratory, Bristol, UK ²Alder Hey Children's Hospital, Liverpool UK ³New Queen Elizabeth Hospital, Birmingham, UK</p>	12:00 – 12:10	<p>10/ CARDIOVASCULAR RISK ASSESSMENT IN PATIENTS ATTENDING A PIONEERING SPECIALIST MULTIDISCIPLINARY NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) CLINIC: A CLINICAL EFFECTIVENESS STUDY <i>Goyale A¹, Misas MG², Roccarina D², Tsochatzis E² and Nair DR¹</i> Royal Free London NHS Foundation Trust, London, NW3 2QG UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London</p>

		⁴ Old Saint Mary's Hospital, Manchester, U		
	12:10 – 12:15	Discussion	12:10 – 12:15	
12:15 - 13:20 (65 mins)	LUNCH, NETWORKING + EXHIBITION			Mead Gallery, 1 st floor, Arts Centre
12:50 – 13:20	FH nurses committee meeting			National Grid Room, 1 st floor, Arts Centre
TBC	Host: Kate HARALAMBOS 12:20 – 12:50 – lunch in exhibition hall 12:50 – 13:20 – FH nurses meeting			
13:20 – 14:20	SESSION H: Medical & Scientific		SESSION I: Primary & Health Care	
	Butterworth Hall, Arts Centre		Cinema, Arts Centre	
	Co-chairs:		Co-chairs: <i>Arun GUPTA + Tracy WALL</i>	
	13:20 – 13:40 (20 mins)	SPEAKER 11:	13:20 – 13:40 (20 mins)	HC SPEAKER 11: Diabetes <i>Dr David UNWIN</i> RCGP National Champion for Collaborative Care and Support Planning in Obesity & Diabetes RCGP clinical expert in diabetes Senior Medical Advisor Diabetes.co.uk Partner Norwood Surgery, Southport, UK
	13:40 – 13:50	Discussion	13:40 – 13:50	Discussion
	13:50 – 14:10 (20 mins)	SPEAKER 12:	13:50 – 14:10 (20 mins)	HC SPEAKER 12: Vascular dementia <i>Dr Bernadette MCGUINNESS</i> MD PhD FRCP Clinical Senior Lecturer/Consultant Geriatrician Centre for Public Health, Institute of Clinical Science, Belfast
	14:10 – 14:20	Discussion	14:10 – 14:20	Discussion
14:20 – 14:30	Comfort break			
14:30 – 14:40	Presentation of prizes and awards			Butterworth Hall, Arts Centre
	<i>Dr Alan REES</i> Medical Director, HEART UK			
14:40 – 15:40	Closing Interactive Session: This house believes that Dyslipidaemia rather than Glycaemic control is the major determinant of CVD risk in the patient with T2DM.			Butterworth Hall, Arts Centre
	Chair – <i>Dr Alan REES</i>			
15:40	Conference concludes			